|
|
|
weekly market: Illustrious Week: Indian markets gain on global support
|
|
Saturday, March 19, 2016 |
| | | Market Commentary | | | Illustrious Week: Indian markets gain on global support | | The Indian markets witnessed an illustrious Week on support coming from global markets mainly Asia which lifted investor sentiments in domestic markets. The Sensex and Nifty rose 0.95%-1.25% each for the week ended March 18, 2016. | |
 Major Headlines for the week:
Indian indices:
Welcome to the 'Weekly Market Wrap' for Friday, March 18, 2016 where the positive cues from global markets aided gains in Indian stocks last week. The S&P BSE Sensex rose in three out of five trading sessions. The 50-unit Nifty 50 index rose in four out of five trading sessions.
The upmove on the domestic bourses was a part of the upmove in Asian stocks triggered by stronger currencies relative to the US dollar on the heels of the US Federal Reserve slashing its projections for rate increases to two in 2016 from an earlier projection of four after keeping rates unchanged at the conclusion of a two-day monetary policy review on Wednesday, 16 March 2016.
Fewer US interest rates hikes could support demand for emerging-market assets because investors have less incentive to draw out money from risky assets in their search for higher yields in the US.
The BSE Mid-Cap index rose 0.29%. The BSE Small-Cap index rose 0.30%. Both these indices underperformed the Sensex.
The Sensex rose 234.75 points or 0.95% to settle at 24,952.74 in the week ended on Friday, 18 March 2016. The gains for the Nifty were higher in percentage terms than those for the Sensex. The Nifty rose 94.15 points or 1.25% to settle at 7,604.35. Weekly market trend from March 14 - March 18, 2016
March 14 - Positive cues from global markets aided small upmove for Indian stocks at the onset of the week on Monday. The barometer index, the S&P BSE Sensex, rose 86.29 points or 0.35% to settle at 24,804.28.
March 15 - Pharma stocks and index heavyweights HDFC and ITC led losses as the two key benchmark indices snapped two-day winning streak on Tuesday. The barometer index, the S&P BSE Sensex, fell 253.11 points or 1.02% to settle at 24,551.17.
March 16 - Gains in index heavyweights Infosys and ITC, a strong intraday rebound in another index heavyweight HDFC and recovery in banking and pharma stocks aided a strong intraday rebound for key benchmark indices on Wednesday. The barometer index, the S&P BSE Sensex, rose 131.31 points or 0.53% to settle at 24,682.48.
March 17 - A divergent trend was witnessed between the two key benchmark indices, with the barometer index, the S&P BSE Sensex, registering minuscule losses and the 50-unit Nifty 50 index registering small gains on Thursday. The Sensex fell 5.11 points or 0.02% to settle at 24677.37. The Nifty rose 13.80 points or 0.18% to settle at 7,512.55.
March 18 - After hovering in positive zone throughout the trading session, the two key benchmark indices surged in late trade, with the barometer index, the S&P BSE Sensex and the 50-unit Nifty
 50-unit Nifty 50 index, both, hitting more than ten-week closing high on Friday. The Sensex rose 275.37 points or 1.12% to settle at 24,952.74. The gains for the Nifty were higher in percentage terms than those for the Sensex. The Nifty gained 91.80 points or 1.22% to settle at 7,604.35.
Global indices:
Global markets ended on a mixed note where Shanghai Comp surged 5.15%, Hang Seng jumped 2.34%, Dow Jones surged 2.26% while Nikkei fell 1.26% and CAC40 slipped 0.67%.
 Sectoral and stock screening:
Among the 13 sectors, S&P BSE HC fell 4.52%, S&P BSE CD slipped 2.92% and S&P BSE Metal was down 0.62% while S&P BSE Bankex surged 3.50%, S&P BSE Oil&Gas rose 3.24% and S&P BSE IT gained 3.22%.
| | Looking at the 'A' group stocks, the top three gainers of the week were: Cox & Kings up 13.96%, AIA Engineering rose 12.26% and Persistent Systems up 11.77%
Top three losers of the week were: Lupin down 16.08%, Pfizer fell 15.54% and Rajesh Exports was down 9.67%
FII/MF activity:
The foreign institutional investors (FIIs) have been the net buyers of the Indian stocks to the tune of Rs2867.75 crore as on March 17, 2016 and the domestic investors sold Indian shares worth a net of Rs1194.00 crore as on March 16, 2016. | | TOP MOVERS (GROUP A) |  | | | | | | | | | | AIA Engineering | 926.30 | 12.26 | | | Persistent Systems | 669.75 | 11.77 | | | | | | | | | Rajesh Exports | 600.90 | -9.67 | | | | | | | FII/MF ACTIVITIES | | | | | | | Gross purchase | 18,093.63 | 1,946.70 | | | Gross sale | 15,225.88 | 3,140.70 | | | Net investment | 2,867.75 | -1,194.00 | | | | | | | | *As on March 17, 2016
**As on March 16, 2016 | | | | Market Outlook for the coming week!
In the coming week, the trend in global markets, investment by foreign portfolio investors (FPIs), the movement of rupee against the dollar, and crude oil price movement will dictate trend on the bourses in the absence of any domestic macro economic data.
Next week is a truncated trading week. The stock market will remain shut on Thursday, 24 March 2016, on account of Holi and again on Friday, 25 March 2016, on account of Good Friday.
The next major trigger for the Indian markets is Q4 results of India Inc. The Q4 results season starts during second week of April 2016.
On the global front, existing home sales data in the US will be unveiled on Monday, 21 March 2016. New home sales data in the US will be unveiled on Wednesday, 23 March 2016. US will unveil Q4 gross domestic product (GDP) data on Friday, 25 March 2016. Eurozone Markit PMI Composite index data for March will be unveiled on Thursday, 24 March 2016. | | | | To know more about our products and services, click here. |  | Registered Office: Sharekhan Limited, 10th Floor, Beta Building, Lodha iThink Techno Campus, Off. JVLR, Opp. Kanjurmarg Railway Station, Kanjurmarg (East), Mumbai - 400042, Maharashtra. Tel: 022 - 61150000. Sharekhan Ltd.: SEBI Regn. Nos.: BSE: INB/INF011073351 / BSE-CD ; NSE: INB/INF/INE231073330 ; MSEI: INB/INF261073333 / INE261073330 ; DP: NSDL-IN-DP-NSDL-233-2003 ; CDSL-IN-DP-CDSL-271-2004 ; PMS-INP000000662 ; Mutual Fund-ARN 20669 ; Commodity trading through Sharekhan Commodities Pvt. Ltd.: MCX-10080 ; (MCX/TCM/CORP/0425) ; NCDEX-00132 ; (NCDEX/TCM/CORP/0142) ; NCDEX SPOT-NCDEXSPOT/116/CO/11/20626 ; For any complaints email at igc@sharekhan.com ; Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and Do's & Don'ts by MCX & NCDEX and the T & C on www.sharekhan.com before investing. | | | | "This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This document is subject to changes without prior notice. This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.
The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on a reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as he deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of SHAREKHAN may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.
This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licencing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Either SHAREKHAN or its affiliates or its directors or employees/representatives/clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. The analyst certifies that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. Further, no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document." Compliance Officer: Ms. Namita Amod Godbole; Tel: 022-6115000; e-mail: compliance@sharekhan.com
Contact: myaccount@sharekhan.com | | | |
|
posted by Anonymous @ 4:21 AM  |
|
|
|
|
|
